Skip to content

Amit Singnurkar

2 papers in the library · 4 citations · publishing 2023-2024

Papers

Sort Most recent Most cited

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.

Trials July 3, 2024 Joshua M. Poulin, Gregory E. Bigford, Krista L. Lanctôt et al. 3 citations

Major depressive disorder (MDD) is a leading cause of disability worldwide across domains of health and cognition, affecting overall quality of life. Approximately one third of individuals with depression do not fully respond to treatments (e.g., conventional antidepressants, psychotherapy) and alternative strategies are needed. Recent early phase trials suggest psilocybin may be a safe and...

DOI: 10.1186/s13063-024-08268-6 (opens in new tab) Full text (opens in new tab) Major depressive disorder Psilocybin Magic mushrooms Arterial spin labelling +7

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, proof-of-principle, placebo-controlled and crossover, neuroimaging trial in depression

Research Square December 28, 2023 Joshua M. Poulin, Gregory E. Bigford, Krista L. Lanctôt et al. 1 citation preprint

Abstract Background: Major Depressive Disorder (MDD) is a leading cause of disability worldwide across domains of health and cognition, affecting overall quality of life. Approximately one third of individuals with depression do not fully respond to treatments (e.g., conventional antidepressants, psychotherapy) and alternative strategies are needed. Recent early phase trials suggest psilocybin...

DOI: 10.21203/rs.3.rs-3474764/v1 (opens in new tab) Full text (opens in new tab) Psilocybin Major depressive disorder Default mode network Neuroplasticity +10